Meeting
2022 ASCO Annual Meeting
Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results.
Authors
Olivier Rixe
Quantum Santa Fe, Santa Fe, NM
Olivier Rixe , Shou-Ching Tang , Solmaz Sahebjam , Monica M. Mita , Alain C. Mita , Lee S. Rosen , Arnima Bisht , Abderrahim Fandi , Christian Rohlff , Rutika Mehta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT04064359
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3028)
DOI
10.1200/JCO.2022.40.16_suppl.3028
Abstract #
3028
Poster Bd #
20
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
First Author: Andreea Varga
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2022 ASCO Annual Meeting
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).
First Author: Nusayba Ali Bagegni
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
First Author: Jermaine Coward